Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity
Hits:
Institution:药学院
Title of Paper:Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity
Journal:Journal of Medicianal Chemistry
Document Code:1843556113689186305
Volume:67
Issue:18
Page Number:16480
Number of Words:9
Translation or Not:No
Date of Publication:2024-09
Release Time:2025-02-13
Prev One:Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia
Next One:Design and synthesis of novel benzoic acid derivatives as striatal-enriched protein tyrosine phosphatase (STEP) inhibitors with neuroprotective properties